Tech Company Financing Transactions
Clementia Pharmaceuticals Funding Round
On 1/10/2014, Clementia Pharmaceuticals landed $22.5 million in Series A funding from OrbiMed and BDC Venture Capital.
Transaction Overview
Company Name
Announced On
1/10/2014
Transaction Type
Venture Equity
Amount
$22,500,000
Round
Series A
Investors
OrbiMed (Lead Investor) (David Bonita)
BDC Venture Capital (Jean-Francois Pariseau)
Proceeds Purpose
Proceeds from this Series A round will be used for general operational purposes and to test Clementia's lead product candidate, palovarotene in clinical studies for the treatment of FOP.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4150 Ste-Catherine St. West 550
Montreal QC, H3Z 2Y5
Canada
Montreal QC, H3Z 2Y5
Canada
Phone
Website
Email Address
Not Recorded
Overview
Clementia Pharmaceuticals is focused on developing palovarotene for fibrodysplasia ossificans progressiva (FOP) and other diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Clarissa Desjardins
Chief Financial Officer
Michael Singer
Chief Medical Officer
Donna Grogan
VP - Bus. Development
Jeffrey Packman
VP - Sales
Eric Grinstead
Browse more venture capital transactions:
Prev: 1/9/2014: TraceLink venture capital transaction
Next: 1/10/2014: Vestaron venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on tech company VC transactions. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs